<- Go Home
VolitionRx Limited
VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis, such as sepsis; Nu.Q Discover, a solution to profiling nucleosomes; Nu.Q Cancer for predicting treatment response, monitoring treatment response and disease progression, and amending a patient’s cancer treatment regimen; and Capture-PCR and Capture-Seq, which are isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection. VolitionRx Limited is based in Henderson, Nevada.
Market Cap
$30.7M
Volume
220.2K
Cash and Equivalents
$199.4K
EBITDA
-$21.7M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
$1.5M
Profit Margin
100.00%
52 Week High
$0.94
52 Week Low
$0.21
Dividend
N/A
Price / Book Value
-0.72
Price / Earnings
-0.99
Price / Tangible Book Value
-0.71
Enterprise Value
$40.5M
Enterprise Value / EBITDA
-1.89
Operating Income
-$22.7M
Return on Equity
78.71%
Return on Assets
-148.34
Cash and Short Term Investments
$199.4K
Debt
$11.3M
Equity
-$35.9M
Revenue
$1.5M
Unlevered FCF
-$31.1M
Sector
Health Care Equipment and Supplies
Category
N/A